MB-106 is under clinical development by Mustang Bio and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MB-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MB-106 overview

MB-106 is under investigation for the treatment of refractory and relapsed B-cell non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, burkitt lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma including primary mediastinal b-cell lymphoma and autoimmune diseases. It is administered through intravenous route. The therapeutic candidate constitutes autologous T cells engineered to express chimeric antigen receptor (CAR) with anti-CD20 antibody fragment fused to signaling domains. The drug candidate is developed based on CAR-T cell technology.

Mustang Bio overview

Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.

For a complete picture of MB-106’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.